A Study of Intradermal Administration of ZOSTAVAX™ (V211-051 AM2)

One 0.65 mL injection subcutaneously on Day 1

One approximately 0.22 mL injection subcutaneously on Day 1

Two intradermal injections of approximately 0.15 mL each on Day 1

One intradermal injection of approximately 0.1 mL on Day 1

Two intradermal placebo injections of approximately 0.15 mL each on Day 1

One intradermal placebo injection of approximately 0.1 mL on Day 1